How can providers improve their ability to meet the business and clinical performance targets in their contracts? With tighter operating margins and rising costs, it's a critical concern shared by provider organizations in both the fee-for-service and value-based worlds.

“The doctor’s handwriting is as bad as it’s advertised.” And when it comes to documenting the patient interaction in EHR, taking notes is a challenge on its own. The blunt of it is faced by medical assistants who have to cater to different styles of note-taking for multiple doctors. It does not only need to be consistent and standardized, more importantly, but it should also be beneficial to everyone in the care journey who reviews patient records. Hence, to ensure continuity of care, clinical notes are a vital element in patient care.

In today’s healthcare landscape, organizations rely on data across the care continuum with patient data playing an important role in the care they receive. Inaccurate and low-quality information can impact patient safety and lead to unnecessary testing or improper treatment and medication management. According to Black Book Research, inaccurate patient identification and patient matching issues—which lead to repeated medical care due to duplicate records—cost hospitals an average of $1,950 per patient per stay and more than $800 per ED visit.

The CMS's Center for Medicare and Medicaid Innovation (CMMI) recently announced the strategic redesign of their current Global and Professional Direct Contracting (GPDC) model.

Meet Joe. He’s a 68-year-old who suffers from chronic obstructive pulmonary disease (COPD).

Today’s special guest, Dr. Subir Roy, Takeda’s Associate Director of Global Medical Affairs, has been at the intersection of pharma, commercial strategy, data, and technology helping drive greater results in drug development, commercialization, and patient outcomes.

Why should biopharma think beyond point solutions to truly change care for the better? A new advisory in STAT has the answers.

The healthcare industry is transitioning to value-based care models. That’s why the medical device industry's ability to continue the development of life-changing innovations will rely on demonstrating how new technology fits under the new value-based paradigm.

While artificial intelligence has already shown value in reducing healthcare costs and improving patient care, certain challenges must be overcome before the next wave of adoption.

Health systems and hospitals are losing revenue and patients in an escalating competition for care services. Challengers—including major retail, pharmacy, telemedicine, and virtual health brands—are thriving, in part by strategically reframing patients as consumers.